Cargando…

A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis

INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaughn, Byron P, Kaiser, Thomas, Staley, Christopher, Hamilton, Matthew J, Reich, Jon, Graiziger, Carolyn, Singroy, Stephanie, Kabage, Amanda J, Sadowsky, Michael J, Khoruts, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330977/
https://www.ncbi.nlm.nih.gov/pubmed/30666146
http://dx.doi.org/10.2147/CEG.S186097
_version_ 1783387067771781120
author Vaughn, Byron P
Kaiser, Thomas
Staley, Christopher
Hamilton, Matthew J
Reich, Jon
Graiziger, Carolyn
Singroy, Stephanie
Kabage, Amanda J
Sadowsky, Michael J
Khoruts, Alexander
author_facet Vaughn, Byron P
Kaiser, Thomas
Staley, Christopher
Hamilton, Matthew J
Reich, Jon
Graiziger, Carolyn
Singroy, Stephanie
Kabage, Amanda J
Sadowsky, Michael J
Khoruts, Alexander
author_sort Vaughn, Byron P
collection PubMed
description INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver disease. Primary sclerosing cholangitis (PSC) is associated with IBD and markedly increases the risk of colon cancer. We hypothesized that secondary bile acids, which are products of microbial metabolism, are increased in PSC patients. AIM: Here, we profiled the fecal bile acid composition and gut microbiota of participants with IBD and PSC, as well as healthy participants. Additionally, we tested the effects of vancomycin, a proposed treatment for PSC, on gut microbiota and fecal bile acid composition in participants with IBD and PSC. METHODS: Fecal samples were collected from patients with IBD, IBD/PSC and healthy controls and fecal bile acids and DNA for microbiota analysis were extracted. Fecal bile acids were averaged over a seven-day period. For subjects with IBD/PSC, oral vancomycin 500mg twice a day was administered and fecal samples were collected for up to eleven weeks. RESULTS: Participants with IBD and PSC had less fecal microbial diversity at baseline relative to controls. While there was some evidence of altered conversion of cholic acid to deoxycholic acid, no substantial differences were found in the fecal bile acid profiles of patients with IBD and PSC (n=7) compared to IBD alone (n=8) or healthy controls (n=8). Oral vancomycin was a potent inhibitor of secondary bile acid production in participants with IBD and PSC, particularly deoxycholic acid, although no changes in liver biochemistry patterns were noted over a two week period. CONCLUSION: In this pilot study, bile acid profiles were overall similar among patients with IBD and PSC, IBD alone, and healthy controls. Microbiota diversity was reduced in those with PSC and IBD compared to IBD alone or healthy controls.
format Online
Article
Text
id pubmed-6330977
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63309772019-01-21 A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis Vaughn, Byron P Kaiser, Thomas Staley, Christopher Hamilton, Matthew J Reich, Jon Graiziger, Carolyn Singroy, Stephanie Kabage, Amanda J Sadowsky, Michael J Khoruts, Alexander Clin Exp Gastroenterol Original Research INTRODUCTION: Inflammatory bowel disease (IBD) is thought to arise from an abnormal immune response to the gut microbiota. IBD is associated with altered intestinal microbial community structure and functionality, which may contribute to inflammation and complications such as colon cancer and liver disease. Primary sclerosing cholangitis (PSC) is associated with IBD and markedly increases the risk of colon cancer. We hypothesized that secondary bile acids, which are products of microbial metabolism, are increased in PSC patients. AIM: Here, we profiled the fecal bile acid composition and gut microbiota of participants with IBD and PSC, as well as healthy participants. Additionally, we tested the effects of vancomycin, a proposed treatment for PSC, on gut microbiota and fecal bile acid composition in participants with IBD and PSC. METHODS: Fecal samples were collected from patients with IBD, IBD/PSC and healthy controls and fecal bile acids and DNA for microbiota analysis were extracted. Fecal bile acids were averaged over a seven-day period. For subjects with IBD/PSC, oral vancomycin 500mg twice a day was administered and fecal samples were collected for up to eleven weeks. RESULTS: Participants with IBD and PSC had less fecal microbial diversity at baseline relative to controls. While there was some evidence of altered conversion of cholic acid to deoxycholic acid, no substantial differences were found in the fecal bile acid profiles of patients with IBD and PSC (n=7) compared to IBD alone (n=8) or healthy controls (n=8). Oral vancomycin was a potent inhibitor of secondary bile acid production in participants with IBD and PSC, particularly deoxycholic acid, although no changes in liver biochemistry patterns were noted over a two week period. CONCLUSION: In this pilot study, bile acid profiles were overall similar among patients with IBD and PSC, IBD alone, and healthy controls. Microbiota diversity was reduced in those with PSC and IBD compared to IBD alone or healthy controls. Dove Medical Press 2019-01-10 /pmc/articles/PMC6330977/ /pubmed/30666146 http://dx.doi.org/10.2147/CEG.S186097 Text en © 2019 Vaughn et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Vaughn, Byron P
Kaiser, Thomas
Staley, Christopher
Hamilton, Matthew J
Reich, Jon
Graiziger, Carolyn
Singroy, Stephanie
Kabage, Amanda J
Sadowsky, Michael J
Khoruts, Alexander
A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title_full A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title_fullStr A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title_full_unstemmed A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title_short A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
title_sort pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330977/
https://www.ncbi.nlm.nih.gov/pubmed/30666146
http://dx.doi.org/10.2147/CEG.S186097
work_keys_str_mv AT vaughnbyronp apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT kaiserthomas apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT staleychristopher apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT hamiltonmatthewj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT reichjon apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT graizigercarolyn apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT singroystephanie apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT kabageamandaj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT sadowskymichaelj apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT khorutsalexander apilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT vaughnbyronp pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT kaiserthomas pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT staleychristopher pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT hamiltonmatthewj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT reichjon pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT graizigercarolyn pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT singroystephanie pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT kabageamandaj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT sadowskymichaelj pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis
AT khorutsalexander pilotstudyoffecalbileacidandmicrobiotaprofilesininflammatoryboweldiseaseandprimarysclerosingcholangitis